De Albert Hofmann a 4-Pro-MET: Historia de las triptaminas

La historia de la investigación sobre triptaminas comienza con una bicicleta. El 19 de abril de 1943, Albert Hofmann pedaleó por Basilea bajo los efectos del LSD – un ergolino, no una triptamina en sentido estricto, pero la chispa que encendió la investigación psicodélica. Lo que siguió: 80 años de investigación, prohibiciones, renacimiento y el desarrollo de sustancias como 4-Pro-MET. Desde los laboratorios de Hofmann en Sandoz hasta las triptaminas sintéticas del siglo XXI.

Albert Hofmann synthesized LSD (lysergic acid diethylamide) at Sandoz Laboratories in Basel, Switzerland in 1938. Five years later came the accident that changed everything. On April 19, 1943 – now commemorated as "Bicycle Day" – Hofmann absorbed a small quantity through his skin and experienced altered perception during his ride home. LSD is a lysergamide, not a tryptamine. But Hofmann's discovery cracked open the door to systematic psychedelic research.

Tryptamines came next. In 1958, Hofmann synthesized psilocybin and psilocin from Psilocybe mexicana mushrooms. By 1960, he'd determined their chemical structures and developed synthetic production methods. These discoveries put 4-substituted tryptamines on the map alongside lysergamides and phenethylamines. And the research boom that followed was staggering: between 1950 and 1970, approximately 1,000 scientific papers were published on psychedelic tryptamines, and an estimated 40,000 patients received psilocybin or LSD in therapeutic settings.

Alexander «Sasha» Shulgin (1925–2014) llevó el trabajo de Hofmann a un nivel sistemático. En su laboratorio privado en California sintetizó y probó cientos de fenetilaminas y triptaminas – entre ellas 4-HO-MET, el metabolito activo de 4-Pro-MET.

TiHKAL (1997) documentó 55 triptaminas con instrucciones de síntesis y protocolos de autoexperimento. Sobre 4-HO-MET (entrada #21) escribió Shulgin: «Qualitatively a lot like psilocin. I started within the first half-hour, and at the max, I felt the same alteration of color and form» – dosis 10–20 mg, duración 4–6 horas.

Su enfoque era simple y brillante: modificar una variable (p. ej., la N-sustitución), mantener el resto constante y documentar los efectos. Esto sentó las bases de la moderna investigación de relaciones estructura-actividad (SAR) en triptaminas. 4-Pro-MET sigue esta tradición: varía el éster en la posición 4 (propioniloxilo en lugar de acetiloxilo) con el mismo patrón N-metil-N-etil.

The modern psychedelic renaissance began in 2006 when Roland Griffiths' team at Johns Hopkins published their landmark psilocybin study – demonstrating its ability to occasion mystical-type experiences with lasting positive effects. Clinical trials followed fast: by 2026, over 15 Phase II/III trials are active or completed for psilocybin alone, targeting treatment-resistant depression, PTSD, alcohol use disorder, and end-of-life anxiety.

The research chemical market expanded in parallel. 4-HO-MET appeared as a designer substance around 2008, 4-AcO-MET and 4-AcO-DMT gained popularity through the mid-2010s, and 4-Pro-MET emerged in August/September 2025 as the latest iteration of the 4-substituted tryptamine prodrug strategy. Each compound applies Shulgin's foundational chemistry to generate legal variants with predictable pharmacological profiles.